What is MetaVia Inc.?
, a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 8.56M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.